Delivering connected devices for tomorrow’s drug delivery challenges
From pressurized metered dose inhalers to connected breath-actuated inhaler platforms and dry powder inhalers, Aptar Pharma’s c-Device solutions are developed to meet the unique data stream objectives of its customers
Aptar Pharma, the leader in respiratory drug delivery systems, is dedicated to supporting customers and patients to effectively treat respiratory diseases such as asthma and COPD.
With 60% of patients failing to comply with their medication regimens, Aptar Pharma strongly believes that patient behavior can be modified using connected, intuitive and user-friendly devices.
Connected devices provide real time data and objective monitoring with digital solutions. This can boost patient engagement, increase dose adherence and improve patient health outcomes – with patients able to manage treatment more effectively. With improved adherence, healthcare systems could see a reduction in chronic disease hospitalizations, and lower healthcare costs to payers.
Aptar Pharma offers customers a range of both add-on and fully-integrated c-Devices, and has partnered with several digital health solution providers to develop a portfolio of c-Devices such as MDIs and DPIs. Aptar Pharma’s team assists customers from concept through to regulatory submission, supporting speed-to-market.
Aptar Pharma is proud to be showcasing its c-Device technology at DDL 2017, in Edinburgh from 6th-8th December. The drug delivery systems provider’s exhibition stand features a dedicated Connectivity Hub, supporting the growing field of connected devices.
Contact Details:
Company name: Aptar Pharma
Website:www.aptar.com/pharma
E-mail: sai.shankar@aptar.com(Director of Connected Health Business Development at Aptar Pharma)
Media Contacts:
Carolyn Penot
Aptar Pharma
+33 1 39 17 20 38
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
